Analysis of INPEFA® (Sotagliflozin) Cost-Effectiveness Published in JACC: Heart Failure, the Peer-Reviewed Journal of the American College of Cardiology

Company Overview - Lexicon Pharmaceuticals is a biopharmaceutical company focused on pioneering medicines that transform patients' lives through innovative drug discovery and development [4][12]. - The company has launched INPEFA® (sotagliflozin) in the United States and is developing a pipeline of other drug candidates targeting various diseases, including neuropathic pain and diabetes [4][12]. Product Information - INPEFA® (sotagliflozin) is an oral inhibitor of SGLT2 and SGLT1, which are proteins involved in glucose regulation [5]. - Sotagliflozin has been studied in clinical trials involving approximately 20,000 patients across multiple populations, including those with heart failure and diabetes [5]. Research Findings - A recent study published in the Journal of Comparative Effectiveness Research concluded that INPEFA is cost-effective for patients with diabetes and recent worsening heart failure, demonstrating a net gain in quality-adjusted life years (QALYs) of 0.425 compared to standard care [2][12]. - The analysis indicated that lifetime QALYs were 4.43 for the INPEFA group versus 4.04 for the placebo group, reinforcing the financial value of INPEFA for the U.S. healthcare system [13][14]. Clinical Implications - The findings suggest that INPEFA not only provides clinical benefits to heart failure patients but also offers significant economic value for payors [14]. - The research supports the use of INPEFA as a cost-effective addition to standard care for patients hospitalized with heart failure and comorbid diabetes [2][12].